Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04976777) involved 54 people in total. Participants were split into two groups: 36 people received an updated version of a dexamethasone eye implant delivery system (called the Updated DEX PS DDS 0.7 mg), and 18 people received the already-approved version of the same delivery system (Approved DEX PS DDS 0.7 mg). The trial was primarily measuring how many participants in each group experienced at least one unwanted medical event (called an adverse event) during the study period. Nearly all participants finished the study — 35 out of 36 in the updated device group, and all 18 in the approved device group. The reported data shows that in the updated device group, 13 out of 36 participants experienced at least one adverse event. In the approved device group, 7 out of 18 participants experienced at least one adverse event. The trial also set out to measure how well the updated applicator device physically performed when delivering the implant into the eye, but no numerical results for that outcome were reported in the data submitted to ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have swelling in the central part of your eye (called macular edema) caused by a blocked vein in your retina (either a branch or central retinal vein occlusion) or by diabetes.
Who may not be able to join:
- You have a condition in the eye being studied that means you cannot safely receive the specific slow-release dexamethasone (steroid) implant used in this trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants Experiencing at Least One Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.